AI-enabled data infrastructure, in service of clinical judgment.
Pharma²⁸'s intelligence model is not technology alone. Rare diseases require human clinical judgment, specialist interpretation and local medical credibility. AI-enabled infrastructure can help organize, compare, prioritize and interpret complex information — but the value comes from combining data with experienced physicians, researchers, institutions and strategic market understanding.
Rare disease data is fragmented by design.
Clinical signals sit in unstructured notes. Cohorts are undercounted. Investigators lack visibility to peers. Real-world evidence remains anecdotal. The result: therapies that struggle to find patients and patients who struggle to be seen.
An intelligence platform, not a diagnostic tool.
Our platform structures data to help clinicians and developers make better decisions. It supports diagnostic pathways — it does not replace them.
Human clinical judgment. AI-enabled infrastructure.
This human-plus-data model allows Pharma²⁸ to support biotech partners with intelligence that is clinically grounded, strategically useful and oriented toward real-world execution.
Disease landscape mapping
Structuring what is known across institutions and geographies.
Patient identification strategy
Where relevant patients may be concentrated.
Diagnostic compatibility assessment
Clinical and laboratory patterns that may matter.
Cohort and center-of-excellence mapping
Physicians and institutions with the right expertise.
Evidence and literature mapping
What evidence already exists in real-world clinical settings.
Clinical feasibility and real-world evidence planning
Turning fragmented information into development decisions.
- 01
Ingest
Consented data streams from partner institutions.
- 02
Structure
Standardized vocabularies, HPO alignment, provenance.
- 03
Model
Phenotypic pattern detection under clinical governance.
- 04
Deliver
Signals returned to clinicians and program teams for review.
Consent, governance, auditability and clinical oversight are prerequisites — not features. We publish our data governance framework.
Let's connect.
If you are exploring international opportunities for a rare disease therapy, clinical program, data initiative or strategic partnership, we would welcome the opportunity to connect.